Professor Barry Porter is a faculty member at Lancaster University in the School of Computing and Communications . His research focuses on emergent software platforms that address software complexity through component models , meta-software platforms , and machine learning . Key areas include distributed systems, cloud integration with sensor nodes, green computing, and real-time visualization. Research Interests : Runtime adaptation in complex systems Self-assembling software architectures Machine learning for code optimization Distributed emergent systems at scale Green computing for multi-core environments Edge-cloud continuum integration Recent Publication Trends : His 2025 work explores genetic improvement for software using speciation algorithms , program geometry projection , and multi-agent decision frameworks . Earlier studies (2022-2024) investigate edge-cloud systems , neural transfer learning , and ecosystem curation in emergent software. Supervision & Projects : He supervises PhD student Ben Craine and leads projects like B-EGI (Bio-Enhanced Genetic Improvement) and BBC Prosperity Partnership for media delivery. Collaborations span environmental IoT, multi-agent learning, and fog computing. Labs & Groups : Affiliated with the Lancaster Intelligent, Robotic and Autonomous Systems Centre , Centre of Excellence in Environmental Data Science , and the Distributed Systems group.
Jeffrey L. Krichmar is a Professor in the Department of Cognitive Sciences and Department of Computer Science at the University of California, Irvine. His academic journey includes a B.S. in Computer Science from the University of Massachusetts Amherst (1983), an M.S. in Computer Science from The George Washington University (1991), and a Ph.D. in Computational Sciences and Informatics from George Mason University (1997). Prior to UCI, he served as Assistant Professor at George Mason University (1997-1999) and Senior Fellow at The Neurosciences Institute (1999-2007). University of California, Irvine (2007-present) George Mason University (1997-1999) The Neurosciences Institute (1999-2007) His research focuses on neurorobotics , exploring how embodied cognition and biologically plausible neural models can enhance robotic systems. Key areas include spiking neural networks , neuromodulation , path planning , and interactive tactile robots for therapeutic applications. His work bridges neuroscience , robotics , and cognitive science , with applications in autonomous vehicles , neuroprosthetics , and AI explainability . Recent publications emphasize spiking neural networks for navigation , neuromodulated attention , and neuromorphic hardware integration. The development of CARLsim, a GPU-accelerated spiking neural network simulator now in version 6.0, represents a major technical contribution. His team's work on socially assistive robots like CARL-SJR targets therapeutic applications for autism and ADHD. Scientific Awards IJCNN 2020 Best Paper Award Finalist for Best Student Paper at IJCNN 2018 Best Paper Award at IEEE IJCNN 2009 Grants include National Science Foundation funding for neural models of decision-making (2009). His lab (Cognitive Anteater Robotics Laboratory) develops systems that use large-scale brain simulations for autonomous behavior , with applications in adaptive robotics , sensorimotor learning , and neuroethology . Current projects explore neuromodulatory influences on attention systems and cognitive flexibility .
Prof. Dr. Sven Panke is a Full Professor and Head of the Department of Biosystems Science and Engineering at ETH Zürich. His research focuses on bioprocess engineering, synthetic biology, and enzymatic process development. Key areas include miniaturized bioreactor systems, microbial engineering for novel metabolite production, and high-throughput screening methodologies. Education: Studied Biotechnology at TU Braunschweig, with postgraduate research at the German National Research Center for Biotechnology and ETH Zurich. Transitioned from industry (DSM) to academia in 2001 as an Assistant Professor, progressing to Associate Professor (2007-2009) before leading the BSS department. Research interests emphasize directed evolution of enzymes, metabolic pathway engineering, and systems biology approaches to optimize microbial production systems. Current projects include bio-indigo synthesis, antimicrobial peptide discovery, and synthetic biology tools for cellular engineering. Labs/Teams: Leads the Bioprocess Engineering Lab at ETH Zurich, collaborating on projects like the E. coli import system design and γ-glutamyltransferase engineering. Active in developing microfluidics platforms for parallel reaction analysis. Grants/Advising: Funded by initiatives in sustainable biomanufacturing and synthetic biology. Supervises graduate students in bioprocess design and microbial systems engineering.
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.
Miler T. Lee is an Associate Professor at the University of Pittsburgh , focusing on gene regulation during early embryonic development through high-throughput experimental and computational genomics. He earned his Ph.D. in Genomics and Computational Biology in 2009 from the University of Pennsylvania under Dr. Junhyong Kim, followed by postdoctoral work with Dr. Antonio Giraldez at Yale University. Joining the university in 2016, his research spans maternal-to-zygotic transition (MZT), RNA stability, pluripotency networks, and evolutionary developmental biology, utilizing model organisms like zebrafish, Xenopus, and Hydractinia symbiolongicarpus. Key Research Themes: Maternally inherited RNA dynamics during embryogenesis Mechanisms of RNA degradation and transcriptome remodeling Evolution of pluripotency networks in hybrid species Role of zinc signaling in fertilization barriers Computational tools for RNA regulation and sensing Scientific Awards: Pan-American Society for Evolutionary Developmental Biology Junior Faculty Award (2024) Outstanding New Investigator – International Xenopus Board (2023) Basil O'Connor Scholar – March of Dimes (2017-2019) Recent publications highlight his work on enhancer classification, RNA degradation mechanisms, and cross-species MZT comparisons. His lab develops innovative methods like RESA for regulatory sequence analysis and studies evolutionary divergence in RNA localization patterns. While the articles span computational and experimental approaches, they consistently address RNA's role in cellular identity, developmental timing, and evolutionary adaptation. Applications include understanding pluripotency, designing RNA biosensors, and elucidating fertilization barriers. Prospective Ph.D. students are encouraged to contact him for opportunities in gene regulation, development, evo-devo, and computational genomics.
Brenda Schulman is a Professor and Director of the Molecular Machines and Signaling Pathways department at the Max Planck Institute of Biochemistry in Martinsried, Germany. She also holds an honorary professorship at the Technical University of Munich's Department of Chemistry and serves as Adjunct Faculty at St. Jude Children's Research Hospital in Memphis, TN, USA. Her research focuses on understanding how ubiquitin and ubiquitin-like proteins regulate cellular processes through protein modification. Dr. Schulman's research interests center on structural biology of the ubiquitin-proteasome system and ubiquitin-like proteins. Her work has shown that hundreds of dynamic multiprotein complexes are transiently converted into different conformations by specialized regulatory factors that control ubiquitin and ubiquitin-like proteins, thereby monitoring virtually all processes in cell biology. She combines biochemical reconstitution, structural analysis, enzymology, protein design, cell biology, and genetics to understand how these molecular machines function. Her research has significant implications for understanding diseases such as cancer, neurodegenerative disorders, and viral infections where defects in ubiquitin pathways are implicated. Her extensive publication record demonstrates expertise in ubiquitin signaling, protein degradation mechanisms, structural biology of E3 ligases, and molecular machines. Her work spans from fundamental mechanisms of ubiquitin chain formation to therapeutic applications in targeted protein degradation. Among her numerous scientific accolades are the Feldberg Prize for Anglo-German Scientific Exchange (2025), ERC Advanced Grant (2023), Louis-Jeantet Prize for Medicine (2023), Gottfried Wilhelm Leibniz Prize (2019), and election to the National Academy of Sciences (2014). She has also received the Dorothy Crowfoot Hodgkin Award from The Protein Society and has been an Investigator of the Howard Hughes Medical Institute. Dr. Schulman leads an active research group that has produced numerous high-impact publications in top journals including Nature, Cell, and Nature Structural & Molecular Biology. Her team has made significant contributions to understanding the structural mechanisms of ubiquitin transfer, E3 ligase specificity, and the role of ubiquitin in cellular quality control pathways. Current research in her lab focuses on deciphering the ubiquitin code and developing novel approaches for targeted protein degradation.
Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.
Katherine E. Varley, PhD is a Huntsman Cancer Institute Investigator and Associate Professor in the Department of Oncological Sciences at the University of Utah. She leads the Varley Lab and is a member of the Nuclear Control of Cell Growth and Differentiation Program, focusing on breast cancer genomics, epigenetics, and biomarker discovery. Her work bridges computational biology with clinical applications to improve breast cancer diagnosis and treatment. Dr. Varley earned her BS in Biology with a concentration in Computational Biology from Cornell University in 2003, followed by a PhD in Computational Biology from Washington University School of Medicine in 2009 under Dr. Robi Mitra. Her postdoctoral training was conducted in Dr. Richard M. Myers' laboratory at the HudsonAlpha Institute for Biotechnology, where she participated in the ENCODE Project Consortium. Her research focuses on using next-generation sequencing and computational analysis to study gene expression, transcription factor binding, and DNA methylation patterns in breast cancer. The Varley Lab investigates epigenetic gene regulation, develops novel molecular methods and bioinformatics approaches, and translates discoveries into clinical tools. Key research areas include Clinical Trial Genomics, Epigenome Engineering, Detecting Circulating Tumor DNA, and identifying Transcription Factors Driving Metastasis, with particular emphasis on triple-negative breast cancer. Analysis of Dr. Varley's publications reveals a consistent trajectory from fundamental genomic mechanisms to clinical translation, with recent work emphasizing biomarker discovery, tumor heterogeneity, and the development of genomic tools for precision oncology. Her research spans cancer biology, genomics, and computational analysis to address critical challenges in breast cancer treatment. Dr. Varley holds multiple patents related to cancer diagnostics and genomic technologies, including targeted sequencing methods, multigene assays for recurrence risk, and biomarkers for triple-negative breast cancer. These inventions reflect her commitment to translating basic research into clinical applications. She actively collaborates with clinical investigators in breast cancer trials and works closely with the Breast and Gynecologic Cancers Disease Center at Huntsman Cancer Institute. Her lab maintains four main research thrusts that collectively address breast cancer from molecular mechanisms to clinical applications, demonstrating a comprehensive approach to improving patient outcomes through genomic technologies.
Joel Blanchard, PhD, is an Associate Professor in the Departments of Neuroscience and Cell, Developmental & Regenerative Biology at the Icahn School of Medicine at Mount Sinai. He is also an Investigator at the Black Family Stem Cell Institute and the Ronald Loeb Center for Alzheimer’s Disease. His research focuses on developing human brain models using induced pluripotent stem cells to study and treat neurodegenerative diseases. Education: BS, St. Lawrence University MLA, Harvard University PhD, The Scripps Research Institute & MIT Research Interests: Dr. Blanchard’s lab is dedicated to understanding the genetic and environmental vulnerabilities that lead to neurodegeneration. His team develops cutting-edge 3D brain organoids and blood-brain barrier models to investigate diseases like Alzheimer’s, Parkinson’s, and ALS. A major focus is on the role of APOE4 in myelination, cholesterol metabolism, and vascular dysfunction. Scientific Awards: Friedman Brain Institute Scholar Award (2021) ISSCR Merit Award (2019) Glenn Foundation Postdoctoral Fellowship (2018) California Institute for Regenerative Medicine Pre-doctoral Fellowship (2011) Funding & Grants: Dr. Blanchard’s lab is currently funded by NASA, NIH, and the Cure Alzheimer’s Fund. Active projects include the development of miBrain (multicellular integrated brain tissue), blood-brain barrier modeling, and APOE4-mediated mechanisms of neurodegeneration. Lab & Team: The Blanchard Lab is a multidisciplinary team of postdocs, graduate students, and research associates. The lab is actively recruiting postdoctoral fellows and is known for its collaborative, innovative environment focused on translational neuroscience.
Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.
Lief Fenno, MD, PhD, is an Assistant Professor at The University of Texas at Austin, affiliated with Dell Medical School’s Department of Psychiatry and Behavioral Sciences and the College of Natural Sciences’ Department of Neurology. He is a board-certified psychiatrist specializing in addiction medicine, particularly medication-assisted treatment (MAT) for opioid use disorder. His research focuses on molecular and viral tools to study neuron circuitry and behavior, with applications in precision medicine for neurological and psychiatric conditions. Fenno earned his MD and PhD from Stanford University and a BA in neurobiology from Harvard University. His research integrates neuroscience, bioengineering, and clinical medicine to develop novel tools for understanding neural circuits. Key interests include optogenetics, chemogenetics, and optical imaging of neuronal activity in awake subjects. The Fenno Lab explores mechanisms of neurological diseases, particularly addiction, and aims to translate findings into clinical treatments. Recent work emphasizes brain-wide mapping of neural circuits, including studies on glutamate neuron subtypes and VTA-lateral habenula interactions. His lab also develops sono-optogenetic technologies and nanotransducers for deep brain stimulation. Fenno’s educational background includes residency in psychiatry and a bioengineering fellowship at Stanford, underscoring his interdisciplinary approach to neuroscientific challenges.
Simon Yang is a Professor in the School of Engineering at the University of Guelph, part of the College of Engineering and Physical Sciences. His research focuses on artificial intelligence, robotics, sensors, control systems, and bio-inspired intelligence. He has contributed to advanced robotics applications, including mobile robot navigation, underwater vehicle control, and agricultural automation. Dr. Yang holds editorial roles for journals such as the International Journal of Robotics and Automation and IEEE Transactions on Cybernetics . His work bridges theoretical advancements with practical implementations in areas like sensor networks, machine learning, and multi-agent systems. Recent projects include developing robust control frameworks for autonomous systems, digital twin applications, and bio-inspired neural network algorithms. His research emphasizes real-world challenges in robotics, environmental monitoring, and precision agriculture, with a focus on integrating AI-driven solutions for enhanced decision-making and system reliability. Professional contributions include advisory roles in multiple journals and conference committees, reflecting his leadership in the field.
Justin Gottschlich is an Adjunct Lecturer in the Computer Science Department at Stanford University, where he teaches the graduate course Machine Programming (CS 329M) . He also serves as Founder, CEO, and Chief Scientist of Merly Inc., a startup focused on machine programming systems to improve software development efficiency and quality. Previously, he led the Machine Programming Research group at Intel Labs, pioneering advancements in automating software development through a fusion of machine learning, programming languages, and systems research. His academic roles include prior positions as Adjunct Professor at University of Colorado-Boulder and Adjunct Assistant Professor at University of Pennsylvania. He has advised numerous graduate students across institutions, contributing to their research in machine programming and related fields. Gottschlich has authored dozens of research papers and holds multiple patents, with his work highlighted by prominent outlets like the Wall Street Journal and Communications of the ACM. He actively contributes to academic committees, including serving as Steering Committee Chair for the ACM SIGPLAN Machine Programming Symposium (MAPS). His research interests span machine programming, autonomous software development, formal methods, and the integration of AI into software engineering practices. Education: PhD in Computer Science from University of Colorado-Boulder Keynote Engagements: LADSIOS (2021), MIT DSAIL (2021), Penn PRECISE (2019) Labs/Teams: Intel Labs Machine Programming Research Group, Merly's R&D Team Grants & Funding: Extensive industry and academic research funding through Intel Labs and Merly
Norbert O. Reich is a Distinguished Professor in the Department of Chemistry & Biochemistry at the University of California, Santa Barbara (UCSB), affiliated with the College of Letters and Science. He joined UCSB in 1987 after completing his Ph.D. at UCSF in 1984 and an NIH postdoctoral fellowship there. His research focuses on enzyme mechanisms, particularly DNA methylation and telomerase, with applications in antibiotic and cancer therapy design. He also develops innovative chemical biology tools, including gold nanoshell-based drug delivery systems and fluorescence-based protein tracking methods. Education: Ph.D. in Chemistry from UCSF (1984). Awards: Regent's Junior Faculty Fellowship (1987), American Cancer Society Faculty Research Award (1991), UC President's Award for Excellence in Undergraduate Research (1994). Research Interests: Epigenetic regulation via DNA methylation in bacteria and mammals Enzyme mechanisms of DNA methyltransferases (e.g., DNMT3A, CcrM) Design of therapeutic inhibitors targeting epigenetic enzymes Light-controlled delivery of proteins/RNA via gold nanoshells Protein-DNA interaction analysis using microfluidic arrays Awards and Recognition: His honors reflect contributions to both research and education, emphasizing his dual impact in science and teaching. Lab and Collaborations: Leads the Reich Lab, collaborating with researchers like Tom Pettus (UCSB) and Erkki Ruoslahti. Projects include antibiotic development, cancer epigenetics, and nanotechnology-driven drug delivery. Future Work: Expanding applications of nanoshell technology for targeted gene silencing and exploring allosteric inhibitors of DNMT3A for cancer treatment.
